INFO & CONTACTS:  +39 02 2390 1

A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)

Phase: Phase I-II clinical trials

Principal Investigator: Dott.ssa Damian Silvia

Main Facility: Unità Studi Clinici di Fase 1 (Early clinical Drug Development Team-ECDD)

Drug: MK-1084, Cetuximab

Pathologies: Advanced Solid Tumours

ClinicalTrials.gov: Read the details about clinical trials

A phase II study with the aim to evaluate the safety, tolerability and efficacy of the MK-1084 administered as single agent or in combination with cetuximab in participants with KRAS G12C mutant advanced solid tumors that have progressed on or after standard systemic treatment or with no satisfactory alternative treatment options (prior KRAS inhibitor therapy excluded). 

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe